ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends

On: April 24, 2026, 10:19 am EDT

URL has been copied successfully!

Share this story:

Previous Post:Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

Next Post:Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook